
TBCRC 002: A phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Author(s) -
C. Vaklavas,
B.S. Roberts,
K.E. Varley,
N.U. Lin,
M.C. Liu,
H.S. Rugo,
S. Puhalla,
R. Nanda,
A.M. Storniolo,
L.A. Carey,
M.N. Saleh,
Y. Li,
Jennifer Delossantos,
W.E. Grizzle,
A.F. Lobuglio,
R.M. Myers,
A. Forero-Torres
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/rr12-1c87
Subject(s) - letrozole , medicine , postmenopausal women , bevacizumab , stage (stratigraphy) , randomized controlled trial , oncology , hormone receptor , breast cancer , open label , gynecology , cancer , aromatase , biology , chemotherapy , paleontology